Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 59,879 | 65,389 | 51,936 | 79,741 | 54,112 |
| Cost of Goods | 17,633 | 17,635 | 14,911 | 27,448 | 16,821 |
| Gross Profit | 42,246 | 47,754 | 37,025 | 52,293 | 37,291 |
| Operating Expenses | 75,135 | 82,905 | 84,763 | 228,899 | 75,674 |
| Operating Income | -32,256 | -34,516 | -46,827 | -176,158 | -37,562 |
| Interest Expense | 6,732 | 5,679 | 5,256 | 5,398 | 5,093 |
| Other Income | 2,373 | 2,726 | 2,558 | 3,652 | 3,510 |
| Pre-tax Income | -36,615 | -37,469 | -49,525 | -177,904 | -39,145 |
| Income Tax | 1,500 | N/A | N/A | N/A | 300 |
| Net Income Continuous | -38,115 | -37,469 | -49,525 | -177,904 | -39,445 |
| Net Income Discontinuous | N/A | -4 | -3,627 | N/A | -101,731 |
| Net Income | $-38,115 | $-37,473 | $-53,152 | $-55,699 | $-141,176 |
| EPS Basic Total Ops | -0.37 | -0.36 | -0.58 | -0.66 | -1.63 |
| EPS Basic Continuous Ops | -0.37 | -0.36 | -0.54 | -2.07 | -0.46 |
| EPS Basic Discontinuous Ops | N/A | 0.00 | -0.04 | N/A | -1.17 |
| EPS Diluted Total Ops | -0.37 | -0.36 | -0.58 | -0.66 | -1.63 |
| EPS Diluted Continuous Ops | -0.37 | -0.36 | -0.54 | -2.07 | -0.46 |
| EPS Diluted Discontinuous Ops | N/A | 0.00 | -0.04 | N/A | -1.17 |
| EPS Diluted Before Non-Recurring Items | -0.37 | -0.36 | -0.54 | -0.62 | -0.74 |
| EBITDA(a) | $-30,803 | $-34,168 | $-45,450 | $-175,285 | $56,412 |